

ASX Announcement

Monash IVF Group Limited (ASX:MVF)

20 August 2025

Independent Review into Brisbane and Clayton Incidents completed

Further to announcements made on 10 April and 10 June 2025, Monash IVF Group Limited (ASX: MVF or the Company) today confirms that the Independent Review undertaken by Fiona McLeod AO SC into the Brisbane and Clayton clinic incidents ("Incidents") has been completed.

The Independent Review report will not be released publicly to protect the privacy of the affected patients.

The Independent Review is a comprehensive examination of both Incidents, which were unrelated, different in nature and occurred some years apart. Both cases involved non-standard IVF treatments and circumstances that would not arise in the vast majority of IVF procedures.

The Independent Review concluded that the Brisbane incident was the result of human error. The Clayton incident resulted from a range of factors that included human error at multiple stages and IT system limitations in the very limited circumstances of an embryo transfer to a partner. Those limitations ultimately made subsequent processes more vulnerable to human error.

The Company has already implemented many of the Independent Review's recommendations. Following its own internal review, additional safeguards and protocols have already been implemented and the Company is committed to implementing the remainder of the recommendations. These additional safeguards and protocols go beyond the recommendations contained in the Independent Review. The cost involved in implementing the recommendations and additional safeguards and protocols are not anticipated to have a material impact on financial performance.

The Company is announcing its FY25 Results on 22 August 2025.

**Commenting on the completion of the Independent Review, Monash IVF Group
Acting CEO Malik Jainudeen said:**

“To the affected patients and everyone who entrusts Monash IVF with their dreams of building a family, we are deeply sorry for the distress these Incidents have caused.

We have implemented or will be implementing the recommendations of the Independent Review and have taken additional measures to reduce the risk of such Incidents occurring in the future because the care and safety of our patients is and will always be at the heart of everything we do.

“For more than 50 years, MVF has been there for patients through more than 50,000 births and we look forward to continuing to support families with their fertility journey.”

Authorised by the Board of Directors

ENDS

For further information please contact:

Malik Jainudeen
Acting CEO & Company Secretary
Monash IVF Group
T: +61 3 9420 8235

Anastasia Salamastrakis
Public Relations Manager
Monash IVF Group
T: 0457603013